IRIS
NATOLI, Clara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.022
EU - Europa 5.971
AS - Asia 5.376
SA - Sud America 748
AF - Africa 69
Continente sconosciuto - Info sul continente non disponibili 19
OC - Oceania 5
AN - Antartide 1
Totale 21.211
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.885
SG - Singapore 2.247
CN - Cina 1.688
IE - Irlanda 1.016
UA - Ucraina 910
IT - Italia 838
SE - Svezia 792
FR - Francia 705
GB - Regno Unito 640
TR - Turchia 634
BR - Brasile 629
DE - Germania 460
VN - Vietnam 300
IN - India 237
FI - Finlandia 166
RU - Federazione Russa 144
CA - Canada 71
AT - Austria 62
PL - Polonia 53
BE - Belgio 49
AR - Argentina 48
HK - Hong Kong 47
MX - Messico 45
JP - Giappone 34
BD - Bangladesh 33
CZ - Repubblica Ceca 30
IQ - Iraq 24
ES - Italia 22
ZA - Sudafrica 22
KR - Corea 19
NL - Olanda 19
EU - Europa 17
EC - Ecuador 16
AE - Emirati Arabi Uniti 12
CO - Colombia 12
EG - Egitto 12
LT - Lituania 12
PK - Pakistan 12
UZ - Uzbekistan 12
ID - Indonesia 11
RO - Romania 11
AL - Albania 10
VE - Venezuela 10
IL - Israele 9
MA - Marocco 8
IR - Iran 7
PE - Perù 7
PY - Paraguay 7
SA - Arabia Saudita 7
UY - Uruguay 7
BO - Bolivia 6
CL - Cile 6
DO - Repubblica Dominicana 6
DZ - Algeria 6
KE - Kenya 6
AU - Australia 5
JO - Giordania 5
LB - Libano 5
NP - Nepal 5
SN - Senegal 5
CH - Svizzera 4
DK - Danimarca 4
GR - Grecia 4
AZ - Azerbaigian 3
BG - Bulgaria 3
ET - Etiopia 3
HR - Croazia 3
KG - Kirghizistan 3
MT - Malta 3
NI - Nicaragua 3
PT - Portogallo 3
TT - Trinidad e Tobago 3
TW - Taiwan 3
AM - Armenia 2
CI - Costa d'Avorio 2
DM - Dominica 2
GT - Guatemala 2
HN - Honduras 2
JM - Giamaica 2
KW - Kuwait 2
KZ - Kazakistan 2
PH - Filippine 2
QA - Qatar 2
TH - Thailandia 2
TN - Tunisia 2
XK - ???statistics.table.value.countryCode.XK??? 2
AF - Afghanistan, Repubblica islamica di 1
AO - Angola 1
AQ - Antartide 1
BH - Bahrain 1
BS - Bahamas 1
BW - Botswana 1
BY - Bielorussia 1
EE - Estonia 1
GE - Georgia 1
HU - Ungheria 1
LU - Lussemburgo 1
MD - Moldavia 1
MK - Macedonia 1
MM - Myanmar 1
Totale 21.205
Salva come PNG Salva come JPEG
Città #
Singapore 1.681
Chandler 1.479
Jacksonville 1.168
Dublin 1.007
Dallas 549
Ashburn 521
Princeton 466
Beijing 452
Southend 414
Izmir 376
Nanjing 342
Los Angeles 264
Wilmington 224
The Dalles 195
Dearborn 189
Ann Arbor 177
Cambridge 174
Santa Clara 173
Altamura 167
New York 154
Boardman 148
Chieti 140
Nanchang 125
Buffalo 113
Tongling 111
Munich 103
Woodbridge 93
Houston 90
Ho Chi Minh City 89
Redondo Beach 70
Dong Ket 68
São Paulo 66
Shenyang 63
Hebei 60
Kunming 54
Tianjin 51
Brussels 47
Council Bluffs 47
Hong Kong 45
Rome 45
Vienna 45
Washington 43
Brooklyn 42
Hanoi 42
Jiaxing 40
Warsaw 40
Chicago 39
Norwalk 37
Nuremberg 37
Atlanta 33
London 33
Tokyo 33
Denver 32
Montreal 32
Stockholm 32
Orem 29
Pescara 29
Boston 28
Helsinki 27
Hyderabad 26
Seattle 25
Changsha 23
Milan 23
Brno 22
Falls Church 22
Poplar 21
Hangzhou 20
Hefei 20
Johannesburg 19
Kocaeli 19
Phoenix 19
Seoul 19
Belo Horizonte 18
Chennai 17
Rio de Janeiro 17
San Francisco 17
San Mateo 17
Lanzhou 16
Manchester 16
Mumbai 16
Toronto 16
Turku 16
Frankfurt am Main 15
Auburn Hills 14
Augusta 14
Mexico City 14
Tappahannock 14
Changchun 13
Düsseldorf 13
Guangzhou 13
Da Nang 12
Grevenbroich 12
Querétaro 12
Shanghai 12
Tashkent 12
Ankara 11
Baghdad 11
Brasília 11
Haiphong 11
Ningbo 11
Totale 13.142
Salva come PNG Salva come JPEG
Nome #
45: L’UTILIZZO DELL’IMMUNOTERAPIA PER IL TRATTAMENTO DELL’ADENOCARCINOMA POLMONARE IN II LINEA: NIVOLUMAB VS PEMBROLIZUMAB 179
A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer. 178
Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer 164
90K (Mac-2 BP) in human milk 162
"Triple positive" early breast cancer: An observational multicenter retrospective analysis of outcome 161
A multidisciplinary group for prostate cancer management: A single institution experience 161
90K (Mac-2 BP) and galectins in tumor progression and metastasis. 159
Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation 150
Breast cancer "tailored follow-up" in Italian oncology units: A web-based survey 148
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. 145
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer 145
Expression of glycoprotein 90K in human malignant pleural mesothelioma: correlation with patients survival. 143
The 90K tumor associated antigen and clinical progression in human immunodeficiency virus infection 141
90K (MAC-2 BP) gene expression in breast cancer and evidence for the production of 90K by peripheral-blood mononuclear cells 140
Impact of BMI on clinical outcome in advanced cancer patients treated with anti‑PD‑1 Immune checkpoint inhibitors: a preliminary analysis 139
90K protein in HIV infection: evidence of its release from peripheral blood mononuclear cells 137
Gli analoghi sintetici delle glicoamine come potenziali nuovi farmaci nella prevenzione delle metastasi 136
A phase II study of cisplatin, epirubicin, vindesine chemotherapy and lonidamine in advanced nonsmall cell lung cancer 134
New Targets for Therapy in Pancreatic Cancer 134
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience 132
A phase I study of 5-day continuous venous infusion of carboplatin (CBDCA) at circadian rhythm-modulated rate 130
Purification and characterization of a 90 kDa protein releasedfrom human tumors and tumor cell lines 130
Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells 130
Trastuzumab Emtansine (T-DM1) in Patients (pts) With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC): results From a Multicenter Retrospective Analysis 129
ABIRATERONE ACETATE FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN CHEMOTHERAPY-NAIVE PATIENTS: AN ITALIAN MULTICENTER 'REAL-LIFE' 1-YEAR STUDY 129
Elevated serum levels of 90K/MAC-2BP predict unresponsiveness to alfa-interferon therapy in chronic HCV hepatitis patients 127
Glicomimetici quali potenziali nuovi farmaci per la prevenzione delle metastasi. 127
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable 127
A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression 127
90k is a serum marker of poor-prognosis in non-hodgkins-lymphoma patients. 125
90K (Mac-2 BP) predicts CD4 decline in human immunodeficiency virus-infected patients with CD4 counts above 200 x 10^6 cells/L 124
An Epigenetic Approach to Pancreatic Cancer Treatment: the Prospective Role of Histone Deacetylase Inhibitors 124
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting 123
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials 123
High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies 122
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients 122
A novel serum test using interferon for early detection of tumor reccurrence in cancer patients after radical surgery. 121
A PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY WITH CISTAPLIN, EPIRUBICIN AND VP – 16 FOR STAGE III UNRESECTABLE NON-SMALL CELL LUNG CANCER 121
A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men. 121
Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction 120
Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin 120
Chemotherapy preoperative for the management of breast cancer locally advanced 119
Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases 118
Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer 118
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 117
Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: A case report 117
Elevated serum levels of a 90,000 daltons tumor-associated antigen in cancer and in infection by human immunodeficiency virus (HIV). 116
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. 116
A phase I study of 5-day continuous venous infusion of carboplatin (CBDCA) at circadian rhythm-modulated rate 115
Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. 114
Expression of tumor associated 90K-antigen in human breast cancer: no correlation with prognosis and response to first-line therapy with tamoxifen 113
Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody. 113
Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting 113
Surgical treatment of adrenal metastases from non small cell lung cancer 112
DNA ploidy and S-phase fraction in pulmonary carcinoids. 112
Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. 111
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study 110
Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial. 110
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 110
Tyrosine kinase inhibitors 110
TGF-β-1 increases 90K tumor associated antigen gene expression by increasing upstream regulatory factor binding to the minimal promoter. 109
A Flow cytometric study of early gastric cancer 109
Chronomodulated infusion of cisplatin, 5-fluorouracil and folinic acid: lack of activity in advanced colorectal cancer. 108
Inhibition of tumor growth and angiogenesis by SP-2, an anti-LGALS3BP antibody 108
Principali effetti collaterali delle terapie mediche 108
BIOLOGICAL INDICATORS OF PROGNOSIS IN HUMAN CANCER: AN EMERGING ROLE FOR LECTIN GALACTOSIDE-BINDING SOLUBLE 3-BINDING PROTEIN (LGALS3BP) 108
Bone marrow micrometastases detected by a monoclonal antibody in patients with breast cancer. 107
Do cut-off values of lymph node ratio and presence of perineural invasion affect survival in breast cancer patients with pathologic N3a lymph node stage? Reply to Kadri Altundag 107
Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter "real life" study 107
Prognostic value of 90K protein in HIV infection 106
Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival 106
Prognostic value of a novel circulating serum 90K antigen in breast cancer 104
90K protein: a new predictor marker of disease progression in human immunodeficiency virus infection. 104
Lack of prognostic value of immunohistochemical determination of epidermal growth-factor receptors in human prostate-cancer. 104
Prognostic value of a novel circulating serum 90K antigen in HIV-infected haemophilia patients. 104
Identification of Subgroups of Early Breast Cancer Patients at High Risk of Nonadherence to Adjuvant Hormone Therapy: Results of an Italian Survey 104
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer 104
Corrigendum to "Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation" 104
Interleukin-30 Promotes Breast Cancer Growth and Progression 103
Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience 103
Fulvestrant (FUL) 500 milligrams as endocrine therapy (ET) for hormone sensitive advanced breast cancer patients (pts). The Ful500 prospective observational trial 103
Tumor-derived microvesicles: The metastasomes. 102
Influenza vaccine indication during anticancer therapy with immune-checkpoint inhibitors: A transversal challenge for patient’s counselling – preliminary analysis of the INVIDIa study 102
A real -life multicenter study on body weight loss and body mass index in advanced Gastric Cancer patients treated with Ramucirumab-based second -line therapy 102
Unknown primary tumors 101
Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study 101
Unusually high level of a tumor-associated antigen in the serum of human immunodeficiency virus-seropositive individuals. 100
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 100
Family history of cancer as surrogate predictor for immunotherapy with anti-PD-1/PD-L1 immune checkpoint inhibitors: The FAMI-L1 study 100
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study 100
Concentrations of Galectin-3 in the Sera of Normal Controls and Cancer Patients 99
Rivaroxaban for cancer-associated cardiac thrombosis 99
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study 99
Expression of the 90K tumor-associated protein in benign and malignant melanocytic lesions. 98
Relationship and predictive role of the dual expression of FGFR and IL8 in metastatic renal cell carcinoma (mRCC) 98
Adherence to hormonal deprivation therapy in prostate cancer in clinical practice: a retrospective, single-centre study 98
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 98
Enzalutamide in patients with castration-refractory prostate cancer: Retrospective, multicenter, real life study 98
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 98
Long-term outcome of breast cancer patients with pathologic N3a lymph node stage 97
Totale 11.884
Salva come PNG Salva come JPEG
Categoria #
all - tutte 86.463
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 86.463
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021826 0 0 0 0 0 287 34 43 97 151 84 130
2021/20221.092 23 33 8 193 114 26 23 69 78 28 131 366
2022/20233.858 310 474 269 470 390 717 200 328 445 37 133 85
2023/20241.589 130 55 119 47 126 552 286 49 25 49 16 135
2024/20253.673 202 692 532 115 86 173 137 218 355 188 418 557
2025/20264.152 674 378 979 925 838 358 0 0 0 0 0 0
Totale 22.056